visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Podocyturia : |
Fecha: | 2018 |
Resumen: | Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi. org/10. 1093/ckj/sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost from detached urinary podocytes. |
Ayudas: | Instituto de Salud Carlos III PI16-02057 Instituto de Salud Carlos III PI18-01366 Instituto de Salud Carlos III RD016-009 |
Nota: | Altres ajuts: The work was supported by Comunidad de Madrid CIFRA2 B2017/BMD-3686. |
Derechos: | Tots els drets reservats. |
Lengua: | Anglès |
Documento: | Article ; altres ; Versió publicada |
Materia: | Fabry ; Podocalyxin ; Podocyte ; Podocyturia ; Synaptopodin |
Publicado en: | Clinical Kidney Journal, Vol. 12 (october 2018) , p. 49-52, ISSN 2048-8513 |
4 p, 452.0 KB |